Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
Femasys (NASDAQ: FEMY) has secured its first European commercial order for FemBloc, its revolutionary non-surgical permanent birth control solution, with a $400,000 USD order from Spain. The company has partnered with Comercial Medico Quirúrgica and Durgalab as distributors, leveraging their experience with similar women's health technologies.
FemBloc represents a breakthrough in permanent contraception, utilizing a proprietary polymer delivery system that creates natural scar tissue in the fallopian tubes. This non-surgical approach eliminates risks associated with traditional surgical sterilization, offering a safer, more accessible, and cost-effective alternative for women seeking permanent birth control.
Femasys (NASDAQ: FEMY) ha ottenuto il suo primo ordine commerciale europeo per FemBloc, la sua rivoluzionaria soluzione permanente di contraccezione non chirurgica, con un ordine da 400.000 USD dalla Spagna. L'azienda ha stretto una partnership con Comercial Medico Quirúrgica e Durgalab come distributori, sfruttando la loro esperienza in tecnologie simili per la salute femminile.
FemBloc rappresenta una svolta nella contraccezione permanente, utilizzando un sistema proprietario di rilascio di polimeri che crea tessuto cicatriziale naturale nelle tube di Falloppio. Questo approccio non chirurgico elimina i rischi associati alla sterilizzazione chirurgica tradizionale, offrendo un'alternativa più sicura, accessibile ed economica per le donne che desiderano una contraccezione permanente.
Femasys (NASDAQ: FEMY) ha asegurado su primer pedido comercial europeo para FemBloc, su revolucionaria solución permanente de control de natalidad no quirúrgico, con un pedido de 400,000 USD desde España. La compañía se ha asociado con Comercial Medico Quirúrgica y Durgalab como distribuidores, aprovechando su experiencia con tecnologías similares en salud femenina.
FemBloc representa un avance en la anticoncepción permanente, utilizando un sistema de liberación de polímeros patentado que crea tejido cicatricial natural en las trompas de Falopio. Este enfoque no quirúrgico elimina los riesgos asociados con la esterilización quirúrgica tradicional, ofreciendo una alternativa más segura, accesible y rentable para las mujeres que buscan control de natalidad permanente.
Femasys (NASDAQ: FEMY)는 혁신적인 비수술 영구 피임 솔루션인 FemBloc에 대해 스페인에서 40만 달러 규모의 첫 유럽 상업 주문을 확보했습니다. 회사는 유사한 여성 건강 기술 경험을 보유한 Comercial Medico Quirúrgica 및 Durgalab와 배급 파트너십을 맺었습니다.
FemBloc은 독자적인 고분자 전달 시스템을 활용하여 나팔관에 자연 흉터 조직을 형성하는 영구 피임 분야의 혁신입니다. 이 비수술적 접근법은 기존 수술적 불임 시술과 관련된 위험을 없애, 영구 피임을 원하는 여성들에게 보다 안전하고 접근 가능하며 비용 효율적인 대안을 제공합니다.
Femasys (NASDAQ: FEMY) a obtenu sa première commande commerciale européenne pour FemBloc, sa solution révolutionnaire de contraception permanente non chirurgicale, avec une commande de 400 000 USD provenant d'Espagne. L'entreprise s'est associée à Comercial Medico Quirúrgica et Durgalab en tant que distributeurs, tirant parti de leur expérience avec des technologies similaires en santé féminine.
FemBloc représente une avancée majeure dans la contraception permanente, utilisant un système propriétaire de délivrance de polymère qui crée un tissu cicatriciel naturel dans les trompes de Fallope. Cette approche non chirurgicale élimine les risques associés à la stérilisation chirurgicale traditionnelle, offrant une alternative plus sûre, accessible et économique pour les femmes recherchant une contraception permanente.
Femasys (NASDAQ: FEMY) hat seinen ersten europäischen kommerziellen Auftrag für FemBloc, seine revolutionäre nicht-chirurgische dauerhafte Verhütungslösung, mit einem Auftrag über 400.000 USD aus Spanien erhalten. Das Unternehmen hat mit Comercial Medico Quirúrgica und Durgalab als Vertriebspartner kooperiert und deren Erfahrung mit ähnlichen Technologien im Bereich Frauengesundheit genutzt.
FemBloc stellt einen Durchbruch in der dauerhaften Empfängnisverhütung dar, indem es ein proprietäres Polymer-Abgabesystem verwendet, das natürliches Narbengewebe in den Eileitern erzeugt. Dieser nicht-chirurgische Ansatz beseitigt die Risiken herkömmlicher chirurgischer Sterilisation und bietet eine sicherere, zugänglichere und kostengünstigere Alternative für Frauen, die eine dauerhafte Verhütung suchen.
- Secured first European commercial order worth $400,000 USD for FemBloc in Spain
- Partnered with experienced distributors who previously commercialized similar technologies like Essure
- Growing product backlog indicates strong market demand
- No comparable alternatives in the market, positioning FemBloc as a unique solution
- Product offers cost advantages over traditional surgical sterilization
- Company needs to scale production to meet anticipated demand
- Success depends on adoption by healthcare providers in new markets
Insights
Femasys' first $400,000 European FemBloc order in Spain represents significant commercial progress for their non-surgical permanent contraceptive technology.
Femasys has secured its first European commercial order for FemBloc, representing a crucial revenue-generating milestone in the company's international expansion strategy. The
FemBloc's technology offers a disruptive approach to permanent contraception by using a proprietary blended polymer that forms natural scar tissue for fallopian tube occlusion. The non-surgical nature eliminates risks associated with traditional surgical sterilization including anesthesia complications, infection potential, and recovery downtime – creating both clinical and economic advantages.
The strategic partnership with Comercial Medico Quirúrgica and Durgalab demonstrates thoughtful market entry planning. These Spanish distributors bring valuable experience commercializing similar technologies like Essure (previously marketed by Conceptus/Bayer), suggesting Femasys has selected partners with established provider networks and regulatory navigation capabilities.
The mention of a "growing backlog" of FemBloc product indicates building demand, though also suggests potential production scaling challenges that Femasys acknowledges it's actively addressing. This first commercial order could accelerate adoption across additional European markets if Spanish implementation proves successful, potentially creating a domino effect for further distribution partnerships.
--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates--
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its first commercial entry into Europe with an order of approximately
“We are proud to be executing on our mission to expand access to FemBloc, an innovative, non-surgical solution and the only advancement in permanent birth control that offers a less invasive alternative to current and formerly available methods,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “To support that mission, we selected our partners in Spain, Comercial Medico Quirúrgica and Durgalab, based on their successful track record commercializing complex women’s health technologies like Essure permanent contraceptive (originally by Conceptus and later acquired by Bayer). Their expertise and provider relationships make them ideal collaborators to introduce FemBloc, which will first become available in Spain, the first country in the world to offer access to this groundbreaking option. With a growing backlog of FemBloc product, we are focused on scaling production to meet anticipated demand as interest builds across Europe.”
Jordi Escorihuela, Chief Executive Officer of Comercial Medico Quirúrgica, commented, “We are honored to partner with Femasys to bring FemBloc to Spain. Building on our experience in women’s health, we are prepared to implement FemBloc efficiently. Our longstanding relationships with healthcare providers and institutions position us to navigate both the public and private healthcare systems and support a successful, scalable rollout of this important advancement.”
Francisco Javier Duran, Chief Executive Officer of Durgalab, added, “We are confident in bringing FemBloc to Spain, supported by its positive safety profile and compelling value proposition. FemBloc offers a meaningful opportunity to meet patient preferences while addressing the evolving priorities of our healthcare systems.”
FemBloc is a first-of-its-kind, non-surgical solution for permanent birth control, addressing a significant unmet need in women’s reproductive health. It uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue for permanent occlusion. In contrast to surgical sterilization, FemBloc eliminates the risks of anesthesia, infection, and recovery downtime, making it safer, more accessible, and significantly more cost-effective. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential. Learn more at www.FemBloc.com.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025. Commercialization of this highly cost effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What is the value of Femasys (FEMY) first European order for FemBloc?
How does FemBloc permanent birth control work?
Who are Femasys' distribution partners for FemBloc in Spain?
What advantages does FemBloc offer over traditional surgical sterilization?
Why did Femasys choose Spain as the first European market for FemBloc?
